The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular Diseases
|
|---|---|
| Published in |
Frontiers in Pharmacology, September 2016
|
| DOI | 10.3389/fphar.2016.00347 |
| Pubmed ID | |
| Authors |
Irina D. Strazhesko, Olga N. Tkacheva, Dariga U. Akasheva, Ekaterina N. Dudinskaya, Ekaterina V. Plokhova, Valentina S. Pykhtina, Anna S. Kruglikova, Natalia V. Kokshagina, Natalia V. Sharashkina, Mikhail V. Agaltsov, Daria A. Kashtanova, Vladimir A. Vygodin, Irina N. Ozerova, Dmitry A. Skvortsov, Daria Vasilkova, Sergey A. Boytsov |
| Abstract |
Background: Telomerase activity (TA) is considered as the biomarker for cardiovascular aging and cardiovascular diseases (CVDs). Recent studies suggest a link between statins and telomere biology that may be explained by anti-inflammatory actions of statins and their positive effect on TA. Until now, this effect has not been investigated in prospective randomized studies. We hypothesized that 12 months of atorvastatin therapy increased TA in peripheral blood mononuclear cells. Methods: In a randomized, placebo-controlled study 100 hypercholesterolemic patients, aged 35-75 years, free of known CVDs and diabetes mellitus type 2 received 20 mg of atorvastatin daily or placebo for 12 months. TA was measured by quantitative polymerase chain reaction. Results: At study end, 82 patients had sufficient peripheral blood mononuclear cells needed for longitudinal analysis. TA expressed as natural logarithms changed from 0.46 ± 0.05 to 0.68 ± 0.06 (p = 0.004) in the atorvastatin group and from 0.67 ± 0.06 to 0.60 ± 0.07 (p = 0.477) in the control group. In multiple regression analysis, atorvastatin therapy was the only independent predictor (p = 0.05) of the changes in TA independently of markers of chronic inflammation and oxidative stress. Atorvastatin therapy was associated with increases in interleukin-6 within the normal range and a tendency toward reduction in blood urea. Conclusion: These initial observations suggest atorvastatin can act as telomerase activator and potentially as effective geroprotector. Trial registration: The trial was registered in ISRCTN registry ISRCTN55050065. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Unknown | 44 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 24% |
| Student > Ph. D. Student | 5 | 11% |
| Other | 4 | 9% |
| Student > Master | 4 | 9% |
| Researcher | 3 | 7% |
| Other | 5 | 11% |
| Unknown | 13 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 42% |
| Biochemistry, Genetics and Molecular Biology | 4 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Unspecified | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 16 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2016.
All research outputs
#20,344,065
of 22,890,496 outputs
Outputs from Frontiers in Pharmacology
#10,123
of 16,187 outputs
Outputs of similar age
#279,615
of 322,482 outputs
Outputs of similar age from Frontiers in Pharmacology
#94
of 159 outputs
Altmetric has tracked 22,890,496 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,187 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,482 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 159 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.